KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
The European Commission has approved Amgen's IMDYLLTRA for treating extensive-stage small cell lung cancer. The approval was based on Phase 3 DeLLphi-304 trial results showing a 40% reduction in mortality risk compared to chemotherapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for IMDYLLTRA in small cell lung cancer, extensive stage
Importance:8/10
Sentiment:
0.85
European Commission approvalsmall cell lung cancerPhase 3 datamortality reduction
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 2:21 PM